이 페이지의 번역은 실험적이며 개발 중입니다. 여러분의 환영합니다!

Tianda Pharmaceuticals 대차 대조표 상태

재무 상태 기준 확인 5/6

Tianda Pharmaceuticals 의 총 주주 지분은 HK$591.9M 이고 총 부채는 HK$104.9M, 이는 부채 대 자기자본 비율을 17.7% 로 가져옵니다. 총자산과 총부채는 각각 HK$917.3M 및 HK$325.4M 입니다.

주요 정보

17.7%

부채 비율

HK$104.85m

부채

이자 보상 비율	n/a
현금	HK$170.87m
주식	HK$591.94m
총 부채	HK$325.35m
총 자산	HK$917.29m

최근 재무 상태 업데이트

Recent updates

Is Tianda Pharmaceuticals (HKG:455) Using Debt In A Risky Way?

Jun 20

There's Reason For Concern Over Tianda Pharmaceuticals Limited's (HKG:455) Massive 26% Price Jump

Mar 27

Estimating The Fair Value Of Tianda Pharmaceuticals Limited (HKG:455)

Mar 02

Is Tianda Pharmaceuticals (HKG:455) Using Debt Sensibly?

May 23

Tianda Pharmaceuticals (HKG:455) Has Debt But No Earnings; Should You Worry?

Dec 06

Does Tianda Pharmaceuticals (HKG:455) Have A Healthy Balance Sheet?

Jan 11

Does Tianda Pharmaceuticals (HKG:455) Have A Healthy Balance Sheet?

Aug 05

Is Tianda Pharmaceuticals (HKG:455) Using Too Much Debt?

Dec 11

재무 상태 분석

단기부채: 455 의 단기 자산 ( HK$344.2M )이 단기 부채( HK$313.3M ).

장기 부채: 455 의 단기 자산( HK$344.2M )이 장기 부채( HK$12.0M ).

부채 대 자본 내역 및 분석

부채 수준: 455 총 부채보다 더 많은 현금을 보유하고 있습니다.

부채 감소: 455 의 부채 대 자기자본 비율은 지난 5년간 0% 에서 17.7% 로 증가했습니다.

대차 대조표

현금 런웨이 분석

과거에 평균적으로 적자를 기록했던 기업의 경우, 최소 1년 이상의 현금 유동성을 보유하고 있는지 평가합니다.

안정적인 현금 활주로: 455 현재 무료 현금 흐름을 기준으로 1년 이상 충분한 현금 활주로를 보유하고 있습니다.

예측 현금 활주로: 455 23.8 1.3 23.8 % 매년.

Tianda Pharmaceuticals 대차 대조표 상태

재무 상태 기준 확인 5/6

주요 정보

최근 재무 상태 업데이트

Is Tianda Pharmaceuticals (HKG:455) Using Debt In A Risky Way?

Is Tianda Pharmaceuticals (HKG:455) Using Debt Sensibly?

Tianda Pharmaceuticals (HKG:455) Has Debt But No Earnings; Should You Worry?

Does Tianda Pharmaceuticals (HKG:455) Have A Healthy Balance Sheet?

Does Tianda Pharmaceuticals (HKG:455) Have A Healthy Balance Sheet?

Is Tianda Pharmaceuticals (HKG:455) Using Too Much Debt?

Recent updates

Is Tianda Pharmaceuticals (HKG:455) Using Debt In A Risky Way?

Tianda Pharmaceutical Technology (Zhuhai) Co., Ltd. Receives Drug Registration Approval of Ibuprofen Suspension

Tianda Pharmaceuticals Limited Approves Final Dividend

Now 24% overvalued after recent price rise

Tianda Pharmaceuticals Limited, Annual General Meeting, Jun 07, 2024

Now 21% overvalued after recent price rise

There's Reason For Concern Over Tianda Pharmaceuticals Limited's (HKG:455) Massive 26% Price Jump

New major risk - Revenue and earnings growth

Tianda Pharmaceuticals Limited Proposes Final Dividend for the Year Ended 31 December 2023

Tianda Pharmaceuticals Limited to Report Fiscal Year 2023 Results on Mar 26, 2024

New minor risk - Share price stability

Now 26% undervalued

Estimating The Fair Value Of Tianda Pharmaceuticals Limited (HKG:455)

Now 29% undervalued

Tianda Pharmaceuticals Limited Announces Executive Changes, Effective 29 August 2023

Tianda Pharmaceuticals Limited Provides Consolidated Earnings Guidance for the Interim Period Ended June 30, 2023

Tianda Pharmaceuticals Limited to Report First Half, 2023 Results on Aug 28, 2023

Now 28% undervalued

Tianda Pharmaceuticals Limited (SEHK:455) entered into an equity transfer agreement to acquire 45% stake in Yunnan Mengsheng Pharmaceutical Co., Ltd from Yunnan Linuo Biotechnology Co., Ltd. for HKD 23.5 million.

Tianda Pharmaceuticals Limited Announces Board Changes

Now 25% undervalued after recent price drop

Is Tianda Pharmaceuticals (HKG:455) Using Debt Sensibly?

Tianda Pharmaceuticals Limited, Annual General Meeting, Jun 27, 2023

Full year 2022 earnings released: HK$0.025 loss per share (vs HK$0.011 loss in FY 2021)

Executive Chairman & MD recently bought HK$2.7m worth of stock

Executive Chairman & MD recently bought HK$448k worth of stock

Executive Chairman & MD recently bought HK$52k worth of stock

Tianda Pharmaceuticals (HKG:455) Has Debt But No Earnings; Should You Worry?

First half 2023 earnings released: HK$0.008 loss per share (vs HK$0.008 loss in 1H 2022)

Tianda Pharmaceuticals Limited to Report First Half, 2023 Results on Nov 25, 2022

Less than half of directors are independent

Executive Chairman & MD recently bought HK$129k worth of stock

Tianda Pharmaceuticals Limited Declares Final Dividend

Tianda Pharmaceuticals Limited, Annual General Meeting, Aug 25, 2022

Tianda Pharmaceuticals Limited Proposes Final Dividend for the Year Ended March 31, 2022, Payable on September 08, 2022

Full year 2022 earnings released

Tianda Pharmaceuticals Limited Proposes Special Dividend for the Year Ended 31 March 2022

Tianda Pharmaceuticals Limited to Report Fiscal Year 2022 Results on Jun 29, 2022

Less than half of directors are independent

Does Tianda Pharmaceuticals (HKG:455) Have A Healthy Balance Sheet?

First half 2022 earnings: Revenues and EPS in line with analyst expectations

Non-Executive Director Lee George Lam has left the company

Does Tianda Pharmaceuticals (HKG:455) Have A Healthy Balance Sheet?

Full year 2021 earnings released: HK$0.013 loss per share (vs HK$0.001 profit in FY 2020)

Full year 2021 earnings released: HK$0.013 loss per share (vs HK$0.001 profit in FY 2020)

Tianda Pharmaceuticals Limited Provides Consolidated Earnings Guidance for the Year Ended 31 March 2021

First half 2021 earnings released: HK$0.007 loss per share

Is Tianda Pharmaceuticals (HKG:455) Using Too Much Debt?

First half 2021 earnings released: HK$0.007 loss per share

Tianda Pharmaceuticals Limited to Report First Half, 2021 Results on Nov 27, 2020

재무 상태 분석

부채 대 자본 내역 및 분석

대차 대조표

현금 런웨이 분석

건강한 기업 발견하기